Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Issue Objectives are not available.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Supriya Lifescience Limited is one of India's key manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs), with a research and development focused, niche product portfolio spanning around 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics and antiallergics. The company is among India's larger exporters of certain specialty molecules, including Chlorpheniramine Maleate and Ketamine Hydrochloride. The company's manufacturing facility carries approvals from several major global regulators, including the US FDA, Europe's EDQM, Australia's TGA, Korea's KFDA, Japan's PMDA, China's NMPA and Health Canada, reflecting the quality standards needed to serve regulated export markets. Exports made up a large and growing share of revenue in the years leading up to the IPO, with the company shipping to more than 80 countries across Europe, Latin America, Asia and North America. The company is led by its founder promoter, who held a controlling stake through the listing. The IPO combined a fresh issue to fund expansion with an offer for sale that provided the promoter a degree of partial liquidity, while the company's underlying API manufacturing and export business continued to grow strongly in the years before the offering.
Supriya Lifescience raised approximately Rs 315 crore from anchor investors ahead of the issue opening, with participation from institutional names including Nippon Life, Aditya Birla Sun Life Insurance and Societe Generale.
Source: RHP • Analysis provided for informational purposes
Last Updated: 19 July 2026, 5:30 AM
Diversified, regulator-approved API portfolio
The company manufactures a niche basket of nearly 40 APIs across multiple therapeutic segments, backed by approvals from major global regulators including the US, Europe, Japan and China.
Strong export franchise
A large and rising share of revenue comes from exports to more than 80 countries, reducing reliance on any single geography.
Leadership in select niche molecules
The company is among India's larger exporters of certain specialty APIs, giving it scale advantages in those product lines.
Track record of strong profitability growth
Revenue and profit both grew significantly in the years leading up to the IPO, reflecting operating momentum ahead of listing.
Concentration in a single promoter
The company is controlled by one individual promoter, so succession or key-person risk is more concentrated than in a multi-promoter structure.
Regulatory and export market dependence
A large share of revenue depends on maintaining regulatory approvals and access in export markets, which can be affected by inspection outcomes or trade policy changes.
Raw material and currency exposure
As a chemical manufacturer with significant export sales, the company is exposed to input cost volatility and currency fluctuations.
Supriya Lifescience Limited
207/208, Udyog Bhavan, Sonawala Road, Goregaon East, Mumbai 400063, Maharashtra, India
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.